Regeneron Pharmaceuticals, Inc. (REGN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Regeneron Pharmaceuticals’s revenue went from $4.9B in fiscal 2016 to $14.3B in fiscal 2025, growth of about 12.8% a year.
Net income in fiscal 2025 was $4.5B, a net margin of 31.4%; the best year in this period was 2021 with $8.1B.
Over the twelve months to September 30, 2026, revenue was $16.9B and net income $4.8B.
Free cash flow was $4.1B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 7% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.9B | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B | $8.5B | $6.6B | $5.1B | $5.9B | $4.9B |
| Gross profit | — | — | — | — | — | — | — | $6.2B | $4.9B | $5.7B | $4.7B |
| Operating income | $4.9B | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B | $3.6B | $2.2B | $2.5B | $2.1B | $1.3B |
| Net income | $4.8B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $896M |
| EPS (diluted) | $45.30 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| R&D | $6.6B | $5.9B | $5.1B | $4.4B | $3.6B | $2.9B | $2.6B | $2.5B | $1.5B | $2.1B | $2.1B |
| Revenue growth | — | +1.0% | +8.3% | +7.8% | −24.3% | +89.1% | +29.6% | +27.4% | −12.4% | +20.8% | +18.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.8B | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B | $2.6B | $2.4B | $2.2B | $1.3B | $1.5B |
| Capital spending | -$1.0B | -$898M | -$756M | -$719M | -$590M | -$552M | -$615M | -$430M | -$383M | -$273M | -$512M |
| Free cash flow | $3.8B | $4.1B | $3.7B | $3.9B | $4.4B | $6.5B | $2.0B | $2.0B | $1.8B | $1.0B | $974M |
| Dividends paid | $383M | $370M | $0 | $0 | — | — | — | — | — | — | — |
| Buybacks | $3.0B | $3.4B | $2.6B | $2.2B | $2.1B | $1.6B | $5.8B | $276M | $4M | $0 | $0 |
| Stock-based pay | $1.0B | $994M | $983M | $885M | $725M | $602M | $432M | $464M | $427M | $507M | $560M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $8.6B | $9.0B | $10.8B | $7.7B | $5.7B | $3.6B | $3.2B | $2.8B | $1.4B | $1.0B |
| Debt | — | $2.3B | $2.2B | $2.1B | $2.0B | $2.0B | $2.0B | $24M | — | — | — |
| Equity | — | $31.3B | $29.4B | $26.0B | $22.7B | $18.8B | $11.0B | $11.1B | $8.8B | $6.1B | $4.4B |
| Total assets | — | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B | $17.2B | $14.8B | $11.7B | $8.8B | $7.0B |
| Shares (diluted) | 106M | 109M | 115M | 114M | 114M | 112M | 115M | 115M | 115M | 116M | 116M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | 93.9% | 95.4% | 96.5% | 96.0% |
| Operating margin | 28.8% | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 33.7% | 49.2% | 35.4% | 27.4% |
| Net margin | 28.5% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% | 20.4% | 18.4% |
| FCF margin | 22.6% | 28.4% | 25.8% | 29.5% | 36.4% | 40.6% | 23.6% | 30.5% | 35.2% | 17.6% | 20.0% |
| ROIC | — | 9.2% | 11.7% | 13.6% | 17.1% | 37.3% | 25.4% | 17.3% | 27.7% | 19.5% | 20.1% |
| ROE | — | 14.4% | 15.0% | 15.2% | 19.1% | 43.0% | 31.9% | 19.1% | 27.9% | 19.5% | 20.1% |
Frequently asked questions
What is Regeneron Pharmaceuticals’s annual revenue?
$14.3B in fiscal 2025 and $16.9B over the twelve months to September 30, 2026.
How much profit does Regeneron Pharmaceuticals make?
Net income was $4.5B in fiscal 2025 (net margin 31.4%).
Is Regeneron Pharmaceuticals’s revenue growing?
Yes: revenue rose 1.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.